title: Salmeterol combined with fluticasone propionate improved COPD in patients during stable stage.
abstract: OBJECTIVE
  To evaluate the clinical effect of inhaled Salmeterol with Fluticasone propionate (50:500 μg) in patients with moderate to severe chronic obstructive pulmonary disease (COPD) during the stable stage of the disease.
  
  
  METHODS
  Sixty patients with moderate to severe COPD were randomly divided into trial and control groups (N=30 each). In the trial group, patients inhaled Salmeterol with Fluticasone (50:500 μg) propionate twice daily via turbuhaler for 3 months. In the control group, patients used slow- released theophylline, 200 mg, twice daily for 3 months; patients took an expectorant (Ambroxol Hydrochloride, 10 ml, three times daily) if necessary. Clinical symptoms and physical signs were graded using St. George's respiratory disease questionnaire (SGRQ). Changes in lung function were assessed.
  
  
  RESULTS
  Indicators of lung function including the values of FEV1, FEV1/FVC, and FEV1/predicted values were significantly higher after treatment in the trial group than in the control group (P<0.05). SGRQ values in the trial group decreased significantly after treatment (P<0.05).
  
  
  CONCLUSIONS
  Inhaled Salmeterol 50 μg and Fluticasone propionate 500 μg can significantly improve the lung function and clinical symptoms of patients with stable moderate to severe COPD.
authors.affiliation: Department of Respiratory Disease, People's Hospital of Xinjiang Uygur Autonomous Region Wulumuqi, Xinjiang 830000, China.
authors.forename: Dongmei
authors.initials: D
authors.lastname: Lu
authors.affiliation: Department of Pharmacy, People's Hospital of Xinjiang Uygur Autonomous Region Wulumuqi, Xinjiang 830000, China.
authors.forename: Junpeng
authors.initials: J
authors.lastname: Ma
authors.affiliation: Department of Respiratory Disease, People's Hospital of Xinjiang Uygur Autonomous Region Wulumuqi, Xinjiang 830000, China.
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Yang
keywords: COPD; Salmeterol; St. George’s respiratory; disease questionnaire; lung function